Physician profile
Mukesh Sinha
NPI 1679552897
$9,406.64
in general payments reported to CMS, 2019-2025
24 companies · $851 in 2025
The $851 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,673 · 2020: $1,807 · 2021: $471 · 2022: $843 · 2023: $1,041 · 2024: $720 · 2025: $851.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,593 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,592.88 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $4,885.57 | 2019-2025 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $699.88 | 2021-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $560.10 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $495.04 | 2019-2025 | Jynarque |
| Opko Pharmaceuticals, LLC | $490.34 | 2019-2025 | Rayaldee |
| Amgen INC. | $269.32 | 2019-2025 | Tavneos, Parsabiv |
| Horizon Therapeutics Plc | $221.48 | 2020-2023 | Krystexxa |
| Medtronic, INC. | $211.85 | 2023 | Ellipsys Vascular Access System |
| Travere Therapeutics, INC. | $190.48 | 2022-2025 | |
| Calliditas Therapeutics US INC. | $167.54 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $163.88 | 2023-2025 | |
| Glaxosmithkline, LLC. | $146.97 | 2021-2024 | Benlysta |
| Mallinckrodt Hospital Products INC. | $138.27 | 2021-2023 | Acthar |
| Ultragenyx Pharmaceutical INC. | $120.01 | 2019-2022 | |
| Baxter Healthcare | $118.48 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $103.94 | 2020-2021 | |
| Lilly USA, LLC | $97.18 | 2020-2025 | Jardiance |
| Ardelyx, INC. | $79.09 | 2024-2025 | Ibsrela |
| Recor Medical INC | $74.28 | 2025 | Paradise Ultrasound Renal Denervation System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.63 | 2023-2024 | Jardiance |
| Aurinia Pharma U.S., INC. | $49.63 | 2023-2024 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $24.67 | 2025 | Empaveli |
| Shire North American Group INC | $17.59 | 2019 | |
| Genzyme Corporation | $17.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mukesh Sinha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.